Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

660
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
660
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Association Areas of the Cortex01:21

Association Areas of the Cortex

10.3K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of cognitive and behavioural impairment in ALS with brain pathology: pTDP-43 versus microglial activation.

Journal of neurology·2026
Same author

Longitudinal changes in MEG-based brain network topology of ALS patients with cognitive/behavioral impairment-An exploratory study.

Network neuroscience (Cambridge, Mass.)·2025
Same author

Cortical and subcortical changes in resting-state neuronal activity and connectivity in early symptomatic ALS and advanced frontotemporal dementia.

NeuroImage. Clinical·2022
Same author

Screening for cognition in amyotrophic lateral sclerosis: test characteristics of a new screen.

Journal of neurology·2021
Same author

Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2020
Same author

Cognitive and behavioral status in Japanese ALS patients: a multicenter study.

Journal of neurology·2020
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Computerized Adaptive Testing System of Functional Assessment of Stroke
05:21

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

6.4K

Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J).

Yasuhiro Watanabe1, Emma Beeldman2, Joost Raaphorst3

  • 1Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.

Journal of the Neurological Sciences
|July 18, 2016
PubMed
Summary
This summary is machine-generated.

The Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J) is a reliable tool for screening behavioral changes in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This validated questionnaire aids in evaluating symptoms and improving patient care.

Keywords:
Amyotrophic lateral sclerosisBehavioral and personality abnormalitiesCaregiversFamily membersFrontotemporal dementiaQuestionnaire

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

34.1K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Computerized Adaptive Testing System of Functional Assessment of Stroke
05:21

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

6.4K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

34.1K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.4K

Area of Science:

  • Neurology
  • Psychiatry
  • Clinical Psychology

Background:

  • Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) share overlapping clinical, genetic, and neuropathological characteristics.
  • Behavioral and personality changes in ALS patients present significant challenges for caregivers.
  • A readily available screening tool is needed to assess these behavioral symptoms effectively.

Purpose of the Study:

  • To translate the Dutch ALS-FTD-Questionnaire into Japanese (ALS-FTD-Q-J).
  • To examine the clinimetric properties, including internal consistency, construct validity, and clinical validity, of the ALS-FTD-Q-J.
  • To assess the utility of the ALS-FTD-Q-J in differentiating between ALS, behavioral variant FTD (bvFTD), and healthy controls.

Main Methods:

  • Multicenter study involving translation and validation of the ALS-FTD-Questionnaire into Japanese.
  • Evaluation of 146 subjects: 92 ALS, 6 ALS-bvFTD, 16 bvFTD, and 32 healthy controls.
  • Assessment of ALS patients using the Frontal Behavioral Inventory (FBI), frontal/executive function, cognition, anxiety/depression, and motor function scales.

Main Results:

  • The ALS-FTD-Q-J demonstrated good internal consistency (Cronbach α=0.92).
  • High correlation with the FBI (r=0.79) supported construct validity.
  • Moderate correlations with anxiety/depression and low correlations with cognitive scales were observed.
  • The ALS-FTD-Q-J successfully discriminated between ALS, (ALS-)bvFTD patients, and controls.

Conclusions:

  • The ALS-FTD-Q-J is a valid and reliable screening tool for behavioral symptoms in Japanese patients with ALS and FTD.
  • This validated questionnaire can aid clinicians in evaluating and managing behavioral changes in these patient populations.
  • The ALS-FTD-Q-J contributes to better care for individuals affected by ALS and FTD, particularly concerning behavioral manifestations.